Improving Tableting Performance of Lactose Monohydrate by Fluid-Bed Melt Granulation Co-Processing
Co-processing is commonly used approach to improve functional characteristics of pharmaceutical excipients to become suitable for tablet production by direct compression. This study aimed to improve tableting characteristics of lactose monohydrate (LMH) by co-processing by fluid-bed melt granulation with addition of hydrophilic (PEG 4000 and poloxamer 188) and lipophilic (glyceryl palmitostearate) meltable binders. In addition to binding purpose, hydrophilic and lipophilic excipients were added to achieve self-lubricating properties of mixture. Co-processed mixtures exhibit superior flow properties compared to pure LMH and comparable or better flowability relative to commercial excipient Ludipress®. Compaction of mixtures co-processed with 20% PEG 4000 and 20% poloxamer 188 resulted in tablets with acceptable tensile strength (>2 MPa) and good lubricating properties (ejection and detachment stress values below 5 MPa) in a wide range of compression pressures. While the best lubricating properties were observed when glyceryl palmitostearate was used as meltable binder, obtained tablets failed to fulfil required mechanical characteristics. Although addition of meltable binder improves interparticle bonding, disintegration time was not prolonged compared to commercial excipient Ludipress®. Co-processed mixtures containing 20% of either PEG 4000 or poloxamer 188 showed superior tabletability and lubricant properties relative to LMH and Ludipress® and can be good candidates for tablet production by direct compression.
Download the full article or continue reading
About this article: Medarević, D.; Djuriš, J.; Krkobabić, M.; Ibrić, S. Improving Tableting Performance of Lactose Monohydrate by Fluid-Bed Melt Granulation Co-Processing. Pharmaceutics 2021, 13, 2165. https://doi.org/10.3390/pharmaceutics13122165
Materials
α-lactose monohydrate (LMH, Sigma Aldrich, St. Louis, MO, USA), polyethylene glycol 4000 (PEG 4000, Sigma Aldrich, St. Louis, MO, USA), poloxamer 188 (P188, Kolliphor® P188, BASF, Ludwigshafen, Germany), glyceryl palmitostearate (GPS, Precirol® ATO 5, Gattefossé, Saint-Priest, France), croscarmellose sodium (Primellose®, DFE Pharma, Goch, Germany), calcium dihydrogen phosphate dihydrate (Emcompress®, JRS Pharma, Rosenberg, Germany) have been used for the preparation of co-processed excipients. Commercially available co-processed excipient Ludipress® (BASF, Ludwigshafen, Germany) has been used for comparison with the prepared co-processed mixtures.